Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

13.81
+0.05000.36%
Post-market: 13.830.0200+0.14%19:05 EDT
Volume:2.84M
Turnover:39.23M
Market Cap:10.71B
PE:-8.67
High:14.08
Open:13.46
Low:13.36
Close:13.76
52wk High:30.98
52wk Low:12.55
Shares:775.37M
Float Shares:130.76M
Volume Ratio:0.93
T/O Rate:2.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5932
EPS(LYR):-1.4439
ROE:-270.95%
ROA:-148.15%
PB:19.61
PE(LYR):-9.56

Loading ...

Assessing Summit Therapeutics (SMMT) Valuation After Recent Share Price Swings

Simply Wall St.
·
Feb 24

Summit Therapeutics Plc : H.c. Wainwright Cuts Target Price to $30 From $40

THOMSON REUTERS
·
Feb 24

Citi adds ‘upside 90-day catalyst watch’ on Summit Therapeutics

TIPRANKS
·
Feb 24

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vir Biotechnology (VIR) and Summit Therapeutics (SMMT)

TIPRANKS
·
Feb 24

Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT) and Community Health (CYH)

TIPRANKS
·
Feb 24

Summit Therapeutics Q4 net loss widens on rise in expenses

Reuters
·
Feb 24

Summit reports FY 2025 GAAP operating expenses of USD 1.09B up 384%

Reuters
·
Feb 24

BRIEF-Summit Therapeutics Q4 Net Income USD -219.2 Million

Reuters
·
Feb 24

Summit Therapeutics Q4 Operating Expenses USD 225 Million

THOMSON REUTERS
·
Feb 24

Summit Therapeutics Inc. published an update to their financial calendar

Reuters
·
Feb 18

Summit Therapeutics (SMMT) Is Up 6.5% After FDA Accepts Ivonescimab BLA With 2026 PDUFA Date

Simply Wall St.
·
Feb 10

Assessing Summit Therapeutics (SMMT) Valuation After FDA Acceptance Of Ivonescimab BLA

Simply Wall St.
·
Feb 05

Summit Therapeutics Grants Stock Options to New Employees

Reuters
·
Jan 31

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jan 31

Analysts Offer Insights on Healthcare Companies: Talkspace (TALK), Ceribell, Inc. (CBLL) and Summit Therapeutics (SMMT)

TIPRANKS
·
Jan 30

Reassessing Summit Therapeutics (SMMT) After Sharp Pullback And DCF Upside Potential

Simply Wall St.
·
Jan 30

BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, Summit, Lockheed Martin

Reuters
·
Jan 29

BUZZ-Summit rises after FDA accepts marketing application for lung cancer drug

Reuters
·
Jan 29

Summit Therapeutics Shares up 5.5% Premarket After US FDA Accepts Co's Application for Ivonescimab Approval

THOMSON REUTERS
·
Jan 29

FDA Accepts Biologics License Application for Summit Therapeutics' Ivonescimab in EGFR-Mutated NSCLC

Reuters
·
Jan 29